Srinivas Myneni, BDS, MS, PhD

1. Myneni SR*, Berk J, Almojaly SA, et al. Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy. Int J Mol Med 2009;23:407-413.

2. Myneni SR*, Settem RP, Connell TD, Keegan AD, Gaffen SL, Sharma A. TLR2 signaling and Th2 responses drive Tannerella forsythia-induced periodontal bone loss. J Immunol 2011;187:501-509.

3. Myneni SR*, Settem RP, Sojar HT, et al. Identification of a unique TLR2-interacting peptide motif in a microbial leucine-rich repeat protein. Biochem Biophys Res Commun 2012;423:577-582.

4. Myneni SR*, Settem RP, Sharma A. Bacteria take control of tolls and T cells to destruct jaw bone. Immunol Invest 2013;42:519-531.

5. Ciancio SG, Marberger AD, Ayoub F, Garlapo DA, Pantera EA, Pantera CT, Al-Mubarak S,  Sobieraj BD,  He DY, Myneni SR. Comparison of 3 intranasal mists for anesthetizing maxillary teeth in adults: A randomized, double-masked, multicenter phase 3 clinical trial. J Am Dent Assoc 2016;147:339-347.e331.

6. Carrion JA, Rajani J, Al Bahrawy M, Myneni SR, Iacono VJ Osteogenic Potential of Gingival Mesenchymal Stem Cells Over Titanium Machined Surfaces. Int J Oral Maxillofac Implants 2017;32:e249–e254.

7. Myneni SR *, Wang HH, Alluri S, Ciancio SG. Phosphate buffer-stabilized 0.1% chlorine dioxide oral rinse for managing medication-related osteonecrosis of the jaw. Am J Dent 2017;30:350-352.

8. Myneni SR ***.  Effect of baking soda in dentifrices on plaque removal. J Am Dent Assoc 2017;148:S4-s9.

9. Myneni SR***, Brocavich K, H HW. Biological strategies for the prevention of periodontal disease: Probiotics and vaccines. Periodontol 2000 2020;84:161-175.

10. Myneni SR***, Wang H, Cooley W, Garcia-Smith E, Shewale J, Ratcliff J. Effectiveness of a Novel Dentifrice Containing Stabilized Chlorine Dioxide, Sarkosyl, and Sodium Fluoride. Dent J (Basel) 2020;8.

11. Rubino CV, Katz BG, Langlois K, Carrion JA, Walker S, Myneni SR #***. Evaluation of different materials used for sealing of implant abutment access channel and the peri-implant sulcus microbiota: A 6-month, randomized controlled trial. Clin Oral Implants Res 2021;32:941-950.

12. Wang HH, Lam C, Myneni SR**. Resolution of a Cystic Endodontic-Periodontal Lesion Utilizing Combined Apicoectomy and Guided Tissue Regeneration: A Case Report. Clin Adv Periodontics 2022;12:94-100.

13. Hajishengallis G, Hasturk H, Lambris JD. C3-targeted therapy in periodontal disease: moving closer to the clinic. Trends Immunol 2021;42:856-864.

Role: Contributing Author.

14. Eli E. Machtei, Georgios Romanos, Philip Kang, Suncica Travan, Stephan Schmidt, Evangelos Papathanasiou, Nikolaos Tatarakis, Moshik Tandlich, Leila H. Liberman, Jacob Horwitz, Seyed Hossein Bassir, Srinivas Myneni, Harlan J. Shiau,Lior Shapira,Nikos Donos, Athena Papas, Joerg Meyle, William V. Giannobile, Panos N. Papapanou, David M. Kim. Repeated delivery of chlorhexidine chips for the treatment of peri-implantitis: A multicenter, randomized, comparative clinical trial. J Periodontol. 2021; 92(1):11-20. 

15. Safina I, Childress LT, Myneni SR, Vang KB,  Biris AS. Cell-Biomaterial constructs for wound healing and skin regeneration. Drug Metab Rev. 2022; 54: 63-94. 

16. Iacono VJ, Bassir HS, Wang HH, Myneni SR*. Peri-implantitis: Effects of Periodontitis and Its Risk Factors - A Narrative Review. FOMM; Issue: Vol 5 (September 2023): Frontiers of Oral and Maxillofacial Medicine

Active/Industry Grants

2024-2027 Grant#102631

Grant Title: Sanofi Pasteur: A Multi-Center, Cross-Sectional Study to Investigate Immunological, Clinical, and Microbiological Biomarkers in Populations with or without Periodontitis and/or Type 2 Diabetes Mellitus in Participants Aged 30-70 Years

Direct Costs# $346,572

Role: PI

2021-2023 Grant #: 93036 Colgate Palmolive Company

Grant Title: Assessment and quantification of 24-hour circadian patterns of oral health.

Direct costs: $191,220

Role: PI

2018-2023 Grant #: 1213500, Rowpar Pharmaceuticals, Inc

Grant Title: The efficacy of Chlorine dioxide as a chemical adjuvant for treatment of Peri-Implant Mucositis.

Direct costs: $105,000

Role: PI

2018-2023 Grant #:1245198. Periovance, Inc. PA

Grant Title: PSR - A multicenter, phase III, prospective, randomized, active comparator study with a parallel group, paired patient study design comparing standard root planing versus a Periodontal Structure Repair device (PSR) to assist with the treatment of pockets caused by periodontal disease.

Direct costs: $280,499

Role: PI

Federal Grants

2021-2024 Grant #: 5SB1DE028213-05 - NIDCR

Grant Title: " Commercialization Readiness for Bone Filler Scaffold Device to Aid in Dental Applications and Reconstruction.

Direct costs: $2M to Nu Shores LLC. Little Rock, Arkansas.

Role: Consultant for GLP studies. ($172,000 – Three years)

Federal Grants (Completed)

2018-2021 Grant #: 4R44DE028213- NIDCR

Grant Title: "Feasibility study of a nanostructural system for bone regeneration in preparation for dental implants." Multiple PI Grant

Direct costs: $800,000

Role: Co-PI. (50% Effort-Equal contribution as PI)

Industry Grants (Completed)

2016-2018 Grant #: 879595, Noveome Biotherapeutics, Pittsburgh, PA

Grant Title: Grant Title: A Randomized, Double-blind, Placebo-controlled Multi-Center Study to Evaluate the Safety, Efficacy, and Treatment Regimen of ST266 in Subjects with Moderate to Severe Periodontitis

Direct costs: $643,000

Role: PI

2016-2018 Grant #: 773713 Dexcel Pharma Ltd.

Grant Title: The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis.

Direct costs: $350,000

Role: Co-I (20% Effort)

American Academy of Periodontology (AAP) Teaching Fellowship, 2017

AAP Educator Scholarship, 2014

Dr. Srinivas Myneni completed his bachelor’s in dental surgery in 2005 at Rajiv Gandhi University of Health Sciences, Bengaluru, India. Upon completing his clinical training, Dr. Myneni moved to the United States to complete a dual PhD/periodontics residency program at the University at Buffalo. Dr. Myneni is a tenured associate professor in the Department of Periodontology and Endodontics at the Stony Brook School of Dental Medicine. In addition, he is the director of the Advanced Dental Education Program in Periodontics and the Director of Periodontal Research in the department. As a surgeon-scientist, Dr. Myneni specializes in the comprehensive surgical management of patients with periodontal diseases and other related systemic conditions. Dr. Myneni’s research and clinical programs are closely integrated. His research addresses the many challenges that clinicians face in the clinical management of patients with a focus on novel therapies for the treatment of periodontitis and peri-implantitis and the influence of circadian rhythm on oral health and disease, all of which have significant implications on the human body functions well beyond the borders of the oral cavity.